INmune Bio Inc.’s Clinical Trials and Financial Results – Пульс новости ‘7.43’

Key Takeaways

• The company reported a net loss of $30 million for the year ended December 31, 2023.
• Its cash and cash equivalents stood at $35.8 million as of December 31, 2023.
• Clinical trial application for XPro in early Alzheimer’s disease accepted in several EU countries.
• INmune Bio will not enroll US patients in the Alzheimer’s trial due to cost and timing constraints.
• The company is pursuing accelerated approval pathways for XPro in the US.
• Positive pilot study results for XPro in advanced Alzheimer’s patients showed increased alpha wave frequency and power.
• A Phase 2 trial for XPro in treatment-resistant depression is planned for the second half of 2024.
• Full enrollment in the Phase 2 XPro trial for Alzheimer’s disease expected by mid-2024.
• Phase 1 prostate cancer trial enrollment to complete by the end of Q3 2024, with Phase 2 enrollment expected in Q2 2025.
• Upcoming webinar to discuss XPro’s potential in promoting remyelination in neurodegenerative diseases.

Company Outlook

• The company is optimistic about the progress and potential of XPro and INKmune in clinical trials.
• Anticipates full enrollment in the Phase 2 XPro trial for Alzheimer’s disease by mid-2024, with top-line data expected six months after the last patient is enrolled.
• INmune Bio’s cash reserves are believed to be sufficient to fund operations into Q4 2024.

Bearish Highlights

• The company will not be enrolling US patients in the Alzheimer’s trial, focusing on EU countries instead.
• INmune Bio reported an increase in net loss to $30 million in 2023 from $27.3 million in 2022.

Bullish Highlights

• Positive results from a pilot study of XPro in advanced Alzheimer’s patients.
• The company has a favorable outlook on the enrollment and progress of its clinical trials.
• INKmune is showing promise as a cancer therapy with minimal side effects.

Misses

• Despite the progress in trials, the company has reported an increase in net losses year over year.

Q&A Highlights

• Executives discussed the unique mechanism of action of XPro and its favorable safety profile.
• The company expressed confidence in the on-schedule enrollment for their clinical trials, which is considered unusual in the industry.
• INmune Bio highlighted the potential of INKmune as a cancer therapy and its differentiation from radioconjugates due to lack of toxicity.

InvestingPro Insights

• INmune Bio Inc.’s latest financial metrics and stock performance reflect a company in the clinical stage with significant potential but also inherent risks.
• The company’s market capitalization stands at $211.81 million, indicating investor confidence in its future prospects despite current financial losses.
• INmune Bio’s Price/Book ratio as of the last twelve months is 5.67, suggesting that the stock is trading at a higher valuation compared to the company’s book value, which could be attributed to investor expectations of future growth.
• Revenue for the last twelve months was reported at $0.15 million, with a notable decline of 58.56% compared to the previous period. This may raise concerns about current sales performance, but it’s not uncommon for clinical-stage biotech companies to have fluctuating revenues due to the nature of their development cycles.

InvestingPro Tips

• Analysts do not anticipate INmune Bio will be profitable this year, which is reflected in the reported net loss and a negative P/E ratio of -7.06. This is typical for companies in the biotech sector that are focused on research and development.
• The stock price has experienced a large uptick over the last six months, with a 73.56% return, indicating strong recent market performance that could interest momentum investors.